Compare funds
XBI and SBIO share 44 stocks, about 29% of XBI and 69% of SBIO (29.1% overlap by weight). Expense ratios: XBI 0.35%, SBIO 0.50%.
At a glance
Expense ratio = the yearly fee, as a share of your money in the fund. The lowest is marked.
| XBI | SBIO | |
|---|---|---|
| Fund | State Street SPDR S&P Biotech ETF | ALPS Medical Breakthroughs ETF |
| Expense ratio | 0.35%Lowest | 0.50% |
| Yearly cost on $10,000 | $35.00 | $50.00 |
| Holdings | 152 | 82 |
| Top 10 holdings | 13.3% | 34.8% |
| Net assets | $10.7B | $161.8M |
| Holdings as of | Jun 30, 2026 | May 31, 2026 |
| Prospectus filed | Oct 26, 2026 | Mar 30, 2026 |
Past returns
Price change plus dividends. “Per year” rows are yearly averages. The highest in each row is in navy.
| XBI | SBIO | |
|---|---|---|
| 1 week | — | — |
| 1 month | — | — |
| 3 months | — | — |
| 6 months | — | — |
| Year to date | — | — |
| 1 year | — | — |
| 3 years, per year | — | — |
| 5 years, per year | — | — |
| Since start of price data, per year | — | — |
Through —. A dash means the fund is younger than the period. Past returns don’t predict future returns.
Shared holdings
Largest first, by the smaller of the funds’ weights.
| Holding | XBI | SBIO |
|---|---|---|
Apogee Therapeutics Inc | 1.49% | 2.93% |
Oruka Therapeutics IncORKA | 1.38% | 1.81% |
Kymera Therapeutics IncKYMR | 1.36% | 4.23% |
Viking Therapeutics IncVKTX | 1.30% | 2.41% |
CG oncology IncCGON | 1.20% | 3.35% |
Dianthus Therapeutics IncDNTH | 1.18% | 2.64% |
Mirum Pharmaceuticals IncMIRM | 1.16% | 3.90% |
Travere Therapeutics IncTVTX | 1.13% | 2.77% |
Alkermes PLCALKS | 1.11% | 4.48% |
Celcuity IncCELC | 1.10% | 3.92% |
Relay Therapeutics IncRLAY | 1.10% | 1.60% |
Spyre Therapeutics IncSYRE | 1.10% | 3.68% |
Vera Therapeutics IncVERA | 1.06% | 1.61% |
ACADIA Pharmaceuticals IncACAD | 0.94% | 2.35% |
Denali Therapeutics IncDNLI | 0.83% | 2.13% |
Ideaya Biosciences IncIDYA | 0.80% | 1.65% |
Sarepta Therapeutics IncSRPT | 0.75% | 1.20% |
Mineralys Therapeutics IncMLYS | 0.71% | 1.59% |
Celldex Therapeutics IncCLDX | 0.70% | 1.33% |
Agios Pharmaceuticals IncAGIO | 0.69% | 1.10% |
Top 20 of 44 shared holdings.
Only in XBI
106 holdings, 70.7% of the fund.
Only in SBIO
38 holdings, 31.5% of the fund.
How this works & disclosures
Holdings come from each fund’s latest public Form N-PORT on SEC EDGAR (as-of dates in the table), so they can be a few months old.
Expense ratios come from the fee table in each fund’s prospectus (Form 485BPOS) on SEC EDGAR, read from its XBRL data; a dash means it wasn’t machine-readable there, so check the prospectus. Yearly cost on $10,000 is simple arithmetic: expense ratio × $10,000, before any change in the fund’s value.
Returns use Yahoo Finance daily closes (15-min delayed source) adjusted for dividends and splits, so dividends are included as if reinvested. 3Y, 5Y and since-start figures are annualized (yearly averages). “Since start” begins on the first day our price source has for the fund; funds that started on different dates aren’t directly comparable. The growth chart is hypothetical, with no taxes or trading costs.
Overlap by weight adds up, for every holding both funds own, the smaller of its two weights. Shared stocks are matched by ticker, ISIN, CUSIP or name.
Data from SEC Form N-PORT, the holdings report funds file with the SEC each quarter; the SEC makes it public about 60 days after the quarter ends. Holdings change; this may be out of date. SURVYR. describes what funds hold and how they have done; it does not manage money or give advice. Not investment advice. Full disclosures
Data from SEC filings. Holdings change; this may be out of date. Not investment advice. Disclosures
Get the market emails
Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdaysIndexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.
Check your inbox to confirm
We sent a link to . Tap it to start your emails. Nothing is sent until you confirm.
Not there in a minute? Check spam, or .
Dev mode No email provider here, so the confirm link is shown: Open confirm link
Free to use. No card, no ads, no auto-renew.
Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Coteau 0.9 · Oct 21, 2026